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and Movement Disorders of Sleep
Gregory S. Carter
Abstract
The treatment of parasomnias and sleep related movement disorders is not 
always pharmacologic, indeed, some of these disorders respond to behavioral 
approaches without the risks of pharmaceuticals. This chapter endeavors to pull 
forward the disorders in which pharmacologic treatment is the best choice and lay 
out the pharmacologic properties of the treatments. It is not the goal of this chapter 
to present an encyclopedic review of the parasomnias and sleep related movement 
disorders. It is, however, the intent of this chapter to comprehensively review 
pharmacologic treatments used in the management of the disorders in which drug 
use is most necessary. The pharmacokinetic and pharmacodynamic properties and 
known risks of these pharmaceuticals are presented and discussed. When more 
than one pharmaceutical is used clinically within a class of drugs, thorough review 
of selected drugs is presented. The chapter includes investigations, mostly human 
studies, of the drugs discussed. The author’s extensive experience in pharmacology, 
neurology, and sleep medicine take the chapter through pharmacological informa-
tion a clinician needs to guide the management of these disorders.
Keywords: Treatment of parasomnias, movement disorders of sleep, pharmacology 
of sleep disorders, comparison of the benzodiazepines, comparison of the dopamine 
receptor agonists, gabapentin and pregabalin for sleep disorders, risks of sleep 
medications, melatonin, restless leg syndrome, alcohol, caffeine, and opiate effects 
on sleep disorders
1. Introduction
Henri Roger first gave us the term “parasomnia” in 1932 [1]. Subsequently, 
parasomnias have been extensively described and classified into non-REM-related 
parasomnias and REM-related parasomnias, so designated for the sleep stage from 
which the parasomnia emerges [2]. Though there is overlap in treatment options 
for the parasomnias, treatment most often follows semiology and pathophysiology. 
Sleep-related movement disorders are likewise varied in their presentations [3]. The 
treatment of parasomnias and sleep-related movement disorders relies on removal or 
avoidance of precipitants, behavioral techniques, prosthetic or dental devices, as well 
as, medications. Multi-pronged approaches including behavioral techniques in addi-
tion to medications may be most effective. The use of medication is still a necessary 
component of care in illnesses with significant immediate and long-term complica-
tions. This includes serious complications to the individual suffering from these sleep 
disorders, as well as, their bed partners and others within their circle of family and 
friends. In the body of this chapter, I will review the parasomnias and sleep-related 
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movement disorders with behavioral and pharmaceutical approaches to treatment. 
Where behavioral approaches alone are much preferred, this chapter will not delve 
into the physiology, psychology or known pathology of the disorder. Where pharma-
ceutical approaches are common, the chapter will briefly discuss the pathophysiology 
of the disorder and the desirable treatment strategies from clinical studies and expert 
opinion. Drug classes will be fully addressed in individual sections. These sections 
will discuss the pharmacokinetics, pharmacodynamics, and adverse effect profiles 
of the more commonly prescribed drugs within these classes, comparing them by 
popularity, desirable properties, and risks of adverse events. Lastly, in the conclusion 
this chapter will briefly review the current controversies of pharmacologic treatment.
2. The parasomnias
The parasomnias can be divided into the non-REM parasomnias, the REM para-
somnias, the overlap parasomnias, and others which defy definition by sleep stage [4]. 
To best understand these differences, it is necessary to have some knowledge of role 
sleep plays in normal physiology. The sleep stages show a cyclic pattern of light sleep 
(N1) proceeding to common sleep (N2), then to slow wave or deep sleep (N3) and 
finally rapid eye movement (REM) sleep. The cycles gradually change with more N3 
sleep in the first half of the night and more REM sleep in the second half of the night. 
These sleep cycles have been shown to serve multiple physiologic and homeostatic 
functions, but for the purposes of this chapter, deep sleep (N3) has been associated 
with the arousal disorders (confusional arousals, sleep walking, and sleep terrors) 
and REM sleep has been associated with dream enactment or REM sleep behavior 
disorders and nightmares. Each of these disorders demand therapeutic approaches 
that may not work for the others, i.e., sedation may be helpful (at least temporarily) 
for REM sleep parasomnias, but be counter-productive in the arousal disorders.
2.1 Clinical evaluation
The clinical differentiation of the parasomnias demands a careful and complete 
history and physical exam. Witnesses to and video recordings of the parasomnia are 
invaluable. Precipitants for parasomnias include sleep-related breathing disorders, 
sleep deprivation and insufficient sleep for age, emotional trauma and chronic 
mental illness, narcolepsy, endocrine disorders including hypothyroidism, diabetes, 
and perimenstrual distress, degenerative brain disorders, such as Parkinsonism and 
dementia with Lewy bodies, head injury and stroke, epileptic and non-epileptic 
seizures, and medications including lithium, neuroleptics, anticholinergics, 
antidepressants, sedative-hypnotics, opioids, and various recreational drugs 
including alcohol. Very high dose caffeine consumption is another concern as is 
current marijuana use and the use of illegal drugs such as fentanyl and cocaine. A 
family history of parasomnia may or may not be present on initial evaluation. A 
thorough physical examination may reveal findings consistent with sleep apnea or 
respiratory compromise, thyroid enlargement or tenderness, neurologic deficits or 
psychiatric abnormalities. Given the spectrum of parasomnias and varying etiolo-
gies underlying them, if the clinician’s assessment misses an important precipitant 
or co-morbidity, pharmacologic management will likely fail or cause adverse effects.
2.2 Arousal disorders
The arousal disorders arise out of deep sleep (N3) and are felt to represent 
parasomnias emerging from difficulty completely awaking from sleep.  
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These disorders consist predominantly of confusional arousals, sleep walking 
and sleep terrors and effect children under 11 years of age more than adults. 
There is a wide variance in reports of prevalence of arousal disorders from 
9–45% of children [2, 4–7]. The lifetime prevalence in individuals over 15 years 
of age falls to 2.9% to 4.2%. The diagnostic criteria are presented in Table 1. 
Genetic factors [8], infections, sleep deprivation, and obstructive sleep apnea 
[9] can all be predisposing factors, whose elimination may prevent recurrent 
events. With the exception of epilepsy, pharmacotherapy may not be effective 
and may actually worsen symptoms [10]. Reassurance and behavioral approaches 
such as creating a safe sleeping environment, anticipatory or scheduled awaken-
ings, cognitive behavioral therapy [10, 11], and hypnosis [12] are among the 
non-pharmacologic options.
Use of drugs in the developing brain is a concern for pharmacologists due to 
the extreme plasticity of immature neuronal networks. Another concern for the 
use of pharmaceutical agents in children is the tendency of the disorders to resolve 
spontaneously as a child matures. Proserpio et al. [13] laid out four indications for 
initiation of pharmacotherapy. The first is persistence of frequent episodes despite 
elimination of predisposing factors. The second is high risk of injury. The third is 
significant functional impairment, and the fourth is potential legal consequences. 
In the presence of 2–4, there may not be time to pursue behavioral approaches to 
management.
The most frequently used drugs for arousal disorders are the benzodiazepines. 
Antidepressant drugs have been used less frequently. Of note, none of these drugs 
has an FDA indication for their use in arousal disorders or have any large-scale con-
trolled studies of their efficacy. The very long-acting benzodiazepine, clonazepam, 
has been the most frequently used agent [14–16] though other benzodiazepines 
including alprazolam and diazepam have been used in adult sleep terrors and sleep-
walking. Antidepressant drugs including sertraline, paroxetine [17], clomipramine, 
imipramine [18], and trazodone [19] have been used in small case series. Case 
reports have also shown efficacy in the treatment of arousal disorders for melatonin 
[20, 21], hydroxytryptophan [22, 23], and ramelteon [24].
2.2.1 Sleep-related Hypermotor epilepsy
Nocturnal frontal lobe epilepsy, otherwise known as sleep-related hypermotor 
epilepsy, can present as recurrent, intractable confusional arousals [25, 26]. Routine 
polysomnography is not as helpful in differentiating an arousal disorder from sleep-
related hypermotor epilepsy as is video-electroencephalographic recording in an 
A. Recurrent episodes of incomplete awakening from sleep
B. Inappropriate or absent responsiveness to efforts of others to intervene or redirect the person during 
the episode
C. Limited (e.g., a single visual scene) or no associated cognition or dream imagery
D. Partial or complete amnesia for the episode
E. The disturbance is not better explained by another sleep disorder, mental disorder, medical 
condition, medication or substance use
Notes
The events usually occur during the first third of the major sleep episode
The individual may continue to appear confused and disoriented for several minutes or longer following the episode.
Table 1. 
General diagnostic criteria for disorders of arousal (criteria A-E must be met) [2].
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inpatient epilepsy monitoring center. While this is an expensive evaluation option, 
home video recording via cell phone camera, stereotypical behavior of the events, 
frequency up to nightly, persistence into adulthood, and the presence of a brain 
disorder can guide a clinician’s decision to proceed [27]. In the author’s experience 
in a busy university sleep clinic, less than 5% of adult patients presenting with 
arousal disorders are referred for epilepsy monitoring, however, 30% of the patients 
who were referred for epilepsy monitoring were diagnosed with likely or definite 
sleep-related hypermotor epilepsy. As a side note, treatment trials with anti-seizure 
drugs in these patients are not helpful for differentiation, as the pharmacologic 
control of sleep-related hypermotor epilepsy is often challenging.
2.3 REM parasomnias
The REM sleep related parasomnias most prominently include REM sleep behav-
ior disorder and nightmare disorder [2]. REM sleep behavior disorder is often man-
aged with medications, but nightmare disorder is more often treated with behavioral 
interventions. The prevalence of REM sleep behavioral disorder (REMSBD) is 
unknown but has been estimated to be 0.38% of the general population, increasing in 
frequency with age [28, 29]. It is more prevalent in men and usually emerges after age 
50 [2]. There is a prominent association in older patients with the synucleinopathies 
[30]. The differential in younger patients can be quite wide. This parasomnia can be 
co-morbid with narcolepsy, brain tumors, antidepressant medications, and neurode-
velopmental disorders [2]. Severe obstructive sleep apnea can cause dream enactment 
that mirrors REM sleep behavior disorder [31]. A variety of medications have been 
implicated in the precipitation of REM sleep behavior disorder. Antidepressants 
including venlafaxine, mirtazapine, and selective serotonin reuptake inhibitors, 
but not the dopamine reuptake inhibitor bupropion [32], can precipitate REMSBD. 
Medications including beta-blockers, anticholinesterase inhibitors, and selegiline 
have been reported to precipitate REMSBD [2]. Nightmares may occur in 60–75% of 
children; however, frequent nightmares are far less common occurring in only 1–5% 
of children [33]. Post-traumatic stress disorder is a common cause of nightmares in 
adults [34], but 2–8% of the general population may have troublesome nightmares. 
Various pharmaceuticals can precipitate nightmares. These include drugs affecting the 
neurotransmission of norepinephrine, serotonin, and dopamine such as antidepres-
sants, antihypertensives, and dopamine receptor agonists. In addition, the withdrawal 
of a REM sleep suppressant can precipitate the complaint of nightmares. Varenicline, 
a nicotinic antagonist, may commonly induce nightmares [35]. The clinical manage-
ment of nightmares includes removing as many predisposing factors as possible.
The chapter will not discuss parasomnias, such as exploding head syndrome and 
sleep related hallucinations, that are treated with reassurance and very rarely with 
drugs. Sleep enuresis may occur in 15–20% of five-year-old’s [2]. It is more common 
in boys. Non-pharmacologic treatments are superior when the etiology is obstruc-
tive sleep apnea [36], ingestion of high doses of caffeine or psychosocial stressors. 
Nightly desmopressin is used when indicated for frequent intractable sleep enuresis. 
Pharmacologic management is necessary for urinary tract infections, diabetes 
insipidus, diabetes mellitus, or nocturnal epilepsy [2]. Fortunately, improvement 
occurs with age in these children.
3. Sleep related movement disorders
The sleep related movement disorders consist of restless leg syndrome, periodic 
limb movement disorder, sleep related leg cramps, sleep related bruxism, the sleep 
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related rhythmic movement disorders, sleep related myoclonus at sleep onset, 
propriospinal myoclonus at sleep onset [2]. Benign sleep myoclonus of infancy is 
different in that more than half of these infants have neonatal opioid withdrawal 
syndrome [37]. Sleep related rhythmic movement disorders, sleep related myoc-
lonus at sleep onset, and propriospinal myoclonus at sleep onset, and benign 
sleep myoclonus of infancy are very rarely treated with pharmaceuticals once the 
diagnosis is made. Reassurance and building a safe bedroom environment are the 
treatments of choice. Likewise, sleep related bruxism (SRB) is best treated with 
oral devices that protect the teeth. Sleep related bruxism has its highest incidence 
in childhood, occurring in 14–17% of children before decreasing over the life span 
to 3% of older persons [38]. Sleep related breathing disorders are often co-morbid 
with sleep bruxism [39] though the relationship is unclear. More recently, botuli-
num toxin has been used for intractable sleep bruxism [40, 41]. Sleep related leg 
cramps are common. Almost all adults have had a leg cramp during sleep, and likely 
during wakefulness. Nightly leg cramps are reported in 6% of adults older than 60 
[42]. The precipitants of sleep related leg cramps are as numerous as the over-the-
counter dietary supplements used to treat them. The fact that no supplement has 
dominated the market speaks to their success. Predisposing factors include, but are 
not limited to, hypokalemia, hypocalcemia, hypomagnesemia, vigorous exercise, 
prolonged standing, oral contraceptives, diuretics, and long duration of action beta 
blockers [43]. Prescription medications including carisoprodol, diltiazem, gaba-
pentin, orphenadrine, verapamil, have been used with success that likely does not 
significantly exceed placebo, presuming there were any controlled trials.
3.1 Periodic limb movement disorder/restless leg syndrome
The remaining sleep related movement disorders are the closely related periodic 
limb movement disorder and restless leg syndrome. Restless leg syndrome (RLS) 
is a clinical symptom complex. Periodic limb movements (PLM) are a polysom-
nographic finding seen very frequently with the symptom complex of restless leg 
syndrome. When the symptom complex of restless leg syndrome is absent, the 
polysomnographic finding of periodic limb movements become a disorder when 
there is clinically significant sleep disturbance or impairment in mental, physical, 
social, occupational, educational, behavioral, or other areas of functioning [2]. 
Periodic limb movements are seen on polysomnograms with greater frequency 
as patients grow older, though not all of these patients complain of sleep distur-
bance or nonrestorative sleep. Patients with periodic limb movement disorder can 
develop symptom worsening with prescription drugs including selective serotonin 
reuptake inhibitors, tricyclic antidepressants, lithium, and dopamine receptor 
antagonists. Low brain iron levels as manifested in peripheral blood by low ferritin 
levels and low total iron binding percentage are another precipitant. As with RLS, 
gene variants have been identified accounting for a fraction of affected individu-
als with a family history [3]. Care must be taken on polysomnograms to separate 
arousals secondary to limb movements from arousals due to sleep related breathing 
disorders. Distinction of periodic limb movements of sleep with no secondary 
sleep arousal versus periodic limb movement disorder with secondary arousal can 
be difficult. This is especially true of patients undergoing polysomnograms for 
another sleep pathology, such as suspected sleep related breathing disorder. The 
use of PLM associated cortical electroencephalographic arousals to determine 
clinical significance of periodic limb movements may thus be misleading. Cortical 
arousals as measured by an abrupt change to 3 seconds of 8 cycles per second 
rhythms (or higher frequencies) within 0.5 second of the limb movement [44] 
may be more subjective than the rule would suggest. Thus, the decision to treat or 
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not to treat a patient with a periodic limb movement index of greater than 15 limb 
movements per hour can be dependent on the treating physician’s overall clinical 
assessment. Restless leg syndrome is an urge to move the legs usually accompanied 
by an uncomfortable sensation in the legs. The need to move worsens with rest, 
is relieved by movement, and emerges in a drug naïve patient at a specific time in 
their circadian cycle, usually in the evening [2]. Between 21 and 57% of patients 
will have arm symptoms. Sleep initiation and maintenance may be quite difficult for 
these patients resulting in their seeking medical care. The overall prevalence of RLS 
is estimated to be 5–10% in Europe and the United States but lower in Asia. Both 
prevalence and severity increase with age. Family history (obtained in 40–92% of 
cases) and the female gender confer increased risk. Pregnancy, especially the third 
trimester, has a risk three times greater risk than the general population. Restless 
leg syndrome is a clinical diagnosis that requires differentiation from the pain of 
leg cramps, arthralgias, myalgias, neuropathic pain, neuroleptic-induced akathisia, 
subtle spasticity from myelopathy, and anxiety-induced restlessness and repetitive 
movements. Many of these patients require prescription medications for control 
of symptoms. Medications for RLS and PLM disorder fall into four classes which 
will be discussed in depth later in this chapter. The four classes are the dopamine 
agonists, the alpha 2 delta subunit neuronal voltage-gated calcium channel blockers, 
the benzodiazepines and the opioids.
4. Implications for pharmacological management
The prescription drugs used in parasomnias and sleep related movement 
disorders fall into several classes. The benzodiazepines are broadly used for para-
somnias and sleep related movement disorders. Melatonin is also widely used for 
parasomnias. Antidepressants with various pharmacodynamic properties are often 
used both to suppress parasomnias and treat comorbid mood disorders. Prazosin is 
a drug that has been widely used for nightmares. The dopamine receptor agonists 
are used with great frequency for both periodic limb movements and restless legs 
syndrome. The alpha 2 delta subunit neuronal voltage-gated calcium channel block-
ers are used predominantly for RLS/PLMD and other disorders. The final class of 
prescription drugs is the opioids.
We cannot go further into this chapter without taking into consideration the 
ideal properties of a drug to treat sleep disorders. These properties of oral medica-
tions include good gastro-duodenal absorption, ability to cross the blood brain bar-
rier, a metabolic rate and duration of action that match the need for intervention, 
and a low potential for drug interactions. Low short-term and long-term effects on 
the molecular receptor target are also important. Direct and indirect adverse effects 
are additional determinants of patient compliance and satisfaction.
5. The Benzodiazapines
The benzodiazepines were first synthesized by Leo Sternbach in 1955 [45]. 
The benzodiazepines had activity on the neuronal chloride ionophore augment-
ing the effect of gamma aminobutyric acid (GABA) in facilitating sleep, sedation, 
anti-anxiety effects, and muscle relaxation. Hundreds of benzodiazepines were 
synthesized between 1960 and 1980 [46], but only a few have had commercial 
success. With the marketing of chlordiazepoxide in 1960 and diazepam in 1963 
the benzodiazepines increased rapidly in prescription frequency [47]. The utility 
of these drugs as anti-anxiety agents and sedative hypnotics was important to this 
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rise, but safety characteristics were equally important. The therapeutic window of 
the benzodiazepines was much wider than the barbiturates and the lethal dose for 
50% of animals in toxicology studies of diazepam was ten times that of secobarbital 
[48]. Over 50 years the growth of benzodiazepine prescribing was substantial. 
In 2017 there were 45.0 million alprazolam, 26.4 million lorazepam, 29.2 million 
clonazepam, 12.6 million diazepam, and 7.0 million temazepam prescriptions 
dispensed in the United States [49]. The benzodiazepines were placed in Schedule 
IV of the Controlled Substances Act of 1971. Alprazolam was one of the top three 
prescription drugs diverted to the illicit market. While the benzodiazepines were 
less dangerous than barbiturates due to a wider therapeutic window, there were still 
14 deaths associated with benzodiazepines in 2017, most due to intentional over-
dose. According to the National Institute on Drug Abuse there were a total of 70,630 
overdose deaths in the United States in 2019 [50]. Most of those deaths were due 
to opioids, mainly fentanyl. The benzodiazepines were involved in 9,711 of those 
deaths, usually in combination with opioids. By comparison there were 5,175 deaths 
in 2019 associated with antidepressants. Many dose-related adverse effects of 
benzodiazepines resulted from depression of the central nervous system including 
drowsiness, impaired judgment, diminished motor skills, and anterograde amnesia, 
causing falls and confusion in the elderly, breathing problems in symptomatic 
sleep apnea or chronic pulmonary disease, driving impairment, and worsened job 
performance.
5.1 Pharmacokinetics and pharmacodynamics
The GABA system is the location of the primary pharmacodynamics of the 
benzodiazepines [51]. This system is the major inhibitory system in the central 
nervous system, thus the drug effect producing central nervous system depression. 
The GABA-A receptors upon which the benzodiazepines produce their effect are 
pentameric ligand-gated chloride ion channels. There are 21 different subunit iso-
forms within the GABA-A chloride ionophore. These are divided into eight families 
which within their family share 70% of their amino acid sequences. These subunit 
families are classified into alpha, beta, gamma, delta, epsilon, pi, omega, and rho. 
The first four of these are most important for benzodiazepine action. The structure 
most frequently seen in the brain consists of two alpha subunits and two beta 
subunits and one gamma or, less frequently, one delta subunit [52]. The neurotrans-
mitter GABA binds to the interface between the alpha and beta subunits to open the 
chloride ionophore. Benzodiazepines bind to the interface of the alpha and gamma 
subunits. The benzodiazepine binding produces an allosteric change making the 
GABA receptor more sensitive, producing benzodiazepine clinical effects. Of inter-
est for future drug development, the alpha subunit family contains alpha-1 through 
alpha-6 subunits which vary in benzodiazepine sensitivities and specific clinical 
effects [53, 54]. Thus, alpha subunit composition containing alpha-1 is associated 
with sedation, amnesia, anti-seizure activity, and addiction propensity. Alpha-2 
subunits are associated with anti-anxiety propensity, muscle relaxation, cognitive 
disturbance, and analgesic properties. Alpha-5 subunits are associated with learn-
ing, memory, and muscle relaxation.
While the basic 3 ring skeletal molecular structure of the benzodiazepines is 
the same, different additions to this molecular structure yield important differ-
ences in properties. Classification of these additions to the basic benzodiazepine 
nucleus use 7 groupings, five of which are important to this discussion. The triazolo 
group (alprazolam, triazolam, estazolam) and the imidazo group (midazolam) 
include drugs that are closely related structurally. Likewise, the 3-hydroxy group 
(lorazepam, oxazepam, and temazepam) all have similar molecular structures. The 
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2-keto group, including diazepam and the 7-nitro group including clonazepam are 
significantly different structurally from the other benzodiazepines. These molecular 
structure differences contribute to the pharmacologic properties of these drugs. The 
GABA-A receptors also change in response to exogenous factors including benzodi-
azepine exposure. Internalization of the receptor complex leads to degradation and 
altered composition of the pentameric structure, rendering the receptor complex 
less sensitive and less numerous.
There are two prime factors in the choice of a benzodiazepine, half-life and 
potency. A low potency and long half-life benzodiazepine is diazepam and a low 
potency and short half-life benzodiazepine is temazepam. A high potency and 
long half-life benzodiazepine is clonazepam and two high potency short half-life 
benzodiazepines are alprazolam and lorazepam. The pharmacodynamic effects of 
the benzodiazepines are similar. Thus, pharmacokinetic properties, potency, dosing 
requirements, and efficacy have determined usage. Several of the benzodiazepines 
have been used in the pharmacologic treatment of parasomnias and sleep related 
movement disorders, and as a class may be the most frequent and widely used 
pharmacological management. Four commonly used agents are described below in 
alphabetical order.
5.2 Alprazolam
This triazolo benzodiazepine was approved by the FDA in 1981 for the treatment 
of panic disorder. The doses of alprazolam for panic disorder were very high, up 
to 6–12 mg per day. It quickly became the most widely prescribed benzodiazepine 
shortly after marketing. The oral absorption of alprazolam after a single 1 mg dose 
is rapid with an oral bioavailability of 80–100% and peak plasma concentrations 
in young males occurring within 0.7 to 1.8 hours after administration [55]. It is a 
CYP3A4 substrate subject to multiple metabolic inducers and inhibitors. The meta-
bolic products of hepatic microsomal oxidation yield alpha-hydroxy and 4-hydroxy 
alprazolam which have 10% of the plasma concentrations of the parent drug 
and lower affinity for benzodiazepine receptors. A number of drugs may impair 
metabolism of alprazolam, including fluoxetine [56] and propoxyphene, enhancing 
central nervous system effects. The elimination half-life in young men ranged from 
9 to 16 hours. Healthy elderly men had significantly longer half-lives with a mean of 
19 hours versus a mean of 11 hours in young men [57].
Alprazolam falls into the intermediate range among benzodiazepines in regards 
to lipid solubility (50% of diazepam). This characteristic determines the degree of 
uptake into the brain [58] as well as the speed at which alprazolam enters the brain. 
Several studies have demonstrated that the steady state plasma concentrations 
of alprazolam after multiple dosing are proportional to the daily dose and do not 
change the half-life [59–61].
The general binding characteristics are similar to the other benzodiazepines, 
however, the receptor affinity of alprazolam (Ki) of 3.4 nm is tighter than diaz-
epam’s Ki of 5.3 nm [62]. This reflects the potency enhancement from the chloride at 
position 8 on the phenyl ring along with the triazolo ring. This enhancement is even 
tighter for another triazolobenzodiazepine, triazolam, with its remarkable receptor 
affinity (Ki) of 0.5 nm [63]. A unique characteristic not shared by other benzodiaz-
epines [62] was seen with low doses (0.02–0.05 mg/kg) of alprazolam in mice [64]. 
An increased benzodiazepine receptor number was seen compared to the decreased 
receptor number seen with other benzodiazepines and high dose alprazolam.
Clinical information regarding the use of alprazolam in REM sleep behavioral 
disorder is limited [65]. Published results [66, 67] yield varying utility, though this 
author’s results [68, 69] have been quite positive at doses of alprazolam 0.5 mg at 
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bedtime. Alprazolam would appear to have good pharmacokinetic and pharma-
codynamic properties for use in nocturnal parasomnias when a benzodiazepine is 
indicated. Currently, however, it is not frequently prescribed for that purpose. Of 
note, in the elderly (>65 years old) there is a significant and dramatic dose related 
increase in sedation and neuromotor testing decrement between alprazolam doses 
of 0.5 mg and 2.0 mg [60].
5.3 Clonazepam
Clonazepam is the most common drug used for parasomnias. It is limited to oral 
administration, but has been used widely for panic disorder and psychosis, as well 
as, having anti-seizure properties shared with diazepam, lorazepam, and clobazam. 
This 7-nitro group benzodiazepine differs structurally from other benzodiazepines 
resulting in high potency and tight binding affinity (Ki 2.0 nm) to benzodiazepine 
receptors. Clonazepam is rapidly and completely absorbed after oral administration 
and reaches peak plasma concentrations in 1–4 hours [70]. Absolute bioavailability 
is 90%. It is highly metabolized by the hepatic microsomal system with less than 
2% being excreted unchanged in the urine. The remarkable property of this drug is 
its long half-life of 30–40 hours. The constant presence of the drug with multiple 
dosing results in benzodiazepine downregulation with loss of both high affinity 
binding and receptor number [71, 72]. Specific clonazepam binding was reduced 
by 24.9% with chronic administration. This likely explains the loss of efficacy and 
development of tolerance with multiple dosing. Clonazepam, more than lorazepam 
or alprazolam, produced impairment on neuromotor tasks [73, 74]. Alprazolam 
showed significantly faster recovery on testing performance than either clonaz-
epam or lorazepam even though lorazepam has a similar half-life. Ellinwood et al. 
also found that the equivalent dose of alprazolam was half the dosage level of the 
other two drugs, a phenomenon that could not be explained by receptor affinity. 
The length of impairment with lorazepam was greater than clonazepam presumably 
secondary to its greater lipid solubility.
Clonazepam is currently the suggested treatment for REM sleep behavioral 
disorder with more published studies than other drugs that have been used in this 
disorder [65]. Clonazepam showed efficacy in 80% of 200 patients at the Minnesota 
Regional Sleep Disorders Center [66, 67]. There is concern, however, for the use of 
clonazepam in dementia, gait disorders, and obstructive sleep apnea due to reports 
of worsening of each of these with chronic clonazepam dosing. Aurora et al. [65] 
reviewed the adverse event profile of clonazepam and found reports of sedation, 
impotence, early morning loss of motor coordination, confusion, and memory 
dysfunction.
5.4 Diazepam
Diazepam, within six years of it being marketed, became the most prescribed 
drug in the United States from 1969 to 1982 [49]. Diazepam has chemical proper-
ties of lipid solubility and non-ionization at physiological pH that made absorption 
through the gut wall and cerebral capillaries rapid, allowing potent brain concentra-
tions within minutes. Peak blood levels with oral dosing are achieved in 1–2 hours. 
The half-life varies between 20 and 80 hours making the drug a long-acting agent. 
Diazepam gained multiple uses including anti-anxiety, sedative, anti-seizure, anti-
vertigo, and muscle relaxant effects due to its action on both central and peripheral 
benzodiazepine receptors. It is available in oral, rectal, and parenteral formulations. 
Hepatic metabolism of diazepam produces an active metabolite, desmethyldiaz-
epam (DMD), which at steady state with repeated dosing eventually has a higher 
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plasma concentration than its parent drug. The elimination of DMD occurs much 
more slowly than diazepam with a half-life of 36–96 hours. If diazepam is discon-
tinued, withdrawal symptoms can occur ranging from anxiety to seizures with 
higher doses. Diazepam remains a secondary benzodiazepine for both non-REM 
and REM sleep related parasomnias. It is a tertiary treatment when first and second-
line treatments have failed.
5.5 Lorazepam
Lorazepam has many uses in addition to its indication for anxiety with depres-
sion. It has been used as a hypnotic and as a treatment for panic disorder, alcoholic 
delirium tremens, status epilepticus, and pre-procedural sedation [73]. It is avail-
able in oral and parenteral formulations. Its use for parasomnias and sleep-related 
movement disorders has been limited and Aurora et al. [65] did not report loraz-
epam being used for REM sleep behavior disorder.
Lorazepam is one of the 3-hydroxy group of benzodiazepines. This drug is avail-
able in oral and parenteral formulations and is metabolized by glucuronidation thus 
the absence of concern for hepatic impairment or an active metabolite. It has utility 
for anti- anxiety and anti-seizure applications. It is absorbed quickly after oral 
administration with a time to peak plasma levels of 1–5 hours [70]. Like diazepam, 
lorazepam is highly lipophilic and quickly crosses the blood–brain barrier. It is 
rapidly absorbed when administered orally and has a half-life of 10–20 hours. As 
discussed in Section 4.1b, lorazepam has a longer duration of action than might be 
expected for its elimination half-life. The ortho chloride on the ring structures of 
lorazepam, clonazepam, and triazolam increase receptor binding and thus potency. 
The tighter binding may be the reason for the longer duration of action [73].
6. Melatonin
Endogenous melatonin is a hormone secreted by the pineal gland in tandem with 
the circadian rhythm. Studies of melatonin revealed sedative properties leading to 
its use in sleep disorders [75–77]. Melatonin is considered a dietary supplement by 
the Food and Drug Administration in the United States and thus the formulations 
are not subject to the regulations that govern prescription medications mentioned 
in this chapter.
Buscemi et al. [78] did a clinical review of 14 randomized controlled trials of 
exogenous melatonin for sleep disorders. The meta-analysis showed a reduced sleep 
latency of 11.7 minutes (CI: −18.2, −5.2), but this was most significant in those 
patients with delayed sleep-phase syndrome. All of the patients studied carried 
diagnoses of either insomnia or delayed sleep-phase disorder. No doses higher than 
5 mg per night were used and half the studies used no more than 3 mg per night. Of 
the 222 combined participants, 13 reported headaches, 10 dizziness, 3 nausea, and 
3 drowsiness. In all of these there was no significant difference between melatonin 
and placebo.
Moroni et al. [79] conducted another systematic review looking at 19 published 
studies utilizing different formulations of exogenous melatonin. Most of the studies 
reviewed used low dose melatonin (<5 mg). The immediate-release formulations 
produced a decrease in sleep onset latency and the sustained release formulations 
had a greater effect on reducing wakefulness after sleep onset. Oral formula-
tions of melatonin had variability in both absorption and metabolism. There 
were no adverse effects noted in very short-term therapy among healthy research 
participants.
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The amount of melatonin that enters the systemic circulation is decreased by 
first-pass metabolism. The hepatic enzyme involved in metabolism of melatonin 
is CYP1A2 [80, 81]. This enzyme has higher activity in males, likely contributing 
to the gender differences seen in one study [82] which showed almost three times 
higher systemic circulation concentrations in females. An older group of research 
participants also showed three times the maximal concentration in their systemic 
circulation [83].
The Standards of Practice Committee of the American Academy of Sleep 
Medicine (AASM) published recommendations which included a suggestion that 
melatonin be used for the treatment of REM sleep behavior disorder [65]. They noted 
that melatonin had been shown to be effective with few adverse effects. There are 
actually only a few reports showing efficacy of melatonin in parasomnias [75, 84]. 
This author’s experience in a large university sleep clinic confirms the efficacy of 
melatonin in some patients, but the patients with parasomnias treated successfully 
with melatonin comprise less than half of the patients treated successfully with 
benzodiazepines [68].
Dose related adverse effects were reported including headache, morning sleepi-
ness, and delusions/hallucinations [75]. In another set of AASM recommendations 
for the management of circadian disorders [85] melatonin adverse effects were 
discussed in greater depth. There were no serious adverse effects, however, head-
aches, somnolence, hypotension, hypertension, gastrointestinal upset, and exac-
erbation of alopecia areata were all reported. An increase in depressive symptoms 
[86], impairment of glucose tolerance [87], and reproductive function [88] were 
reported. Studies beyond 3 months of melatonin use and studies in pediatrics were 
and remain scarce. Pediatric concerns were reported including potential effects 
on growth hormone regulation with high dose melatonin (10 mg) [89]. There was 
additional thought that the efficacy in pediatric parasomnias might be related to an 
indirect effect of improving sleep rather than a direct effect of melatonin [65].
In conclusion, melatonin is efficacious in some patients with REM sleep behav-
ioral disorder and possibly other parasomnias with no serious adverse effects.
7. The antidepressants
There have been many antidepressants used in patients with a variety of para-
somnias either as primary or concomitant therapy. Parasomnias can be co-morbid 
with mental health disorders leading to antidepressant treatment. The confounding 
factor is that some parasomnias and sleep-related movement disorders may be 
exacerbated or even elicited by antidepressant therapy [90–94]. Lam et al. [95] used 
a questionnaire to identify patients with parasomnias then confirmed the diagnosis 
via a clinical interview. Of the 1235 participants who completed the interview 22.3% 
had clinically confirmed somnambulism, sleep-related eating disorder, or sleep 
related injury. REM sleep behavior disorder (RSBD) was the cause of sleep related 
injury in 66.7% of the subgroup of participants with sleep related injury. The use 
of selective serotonin reuptake inhibitors (SSRIs) was associated with symptoms of 
RSBD in 5% of participants. Of the 29 participants diagnosed with somnambulism 
34.5% were using sedating antidepressants [96].
Drug-induced RSBD has been further associated with the tricyclic antidepres-
sant clomipramine and the monoamine oxidase inhibitors selegiline and phenelzine 
[94]. In spite of these risks co-morbid psychiatric disorders often lead to treatment 
with antidepressants in individuals with parasomnias. There are also a variety of 
case reports of the effective use of antidepressants for management of parasomnias. 
Imipramine was used successfully in seven children diagnosed with sleep terrors 
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or somnambulism [97]. Paroxetine at a dose of 40 mg in the morning was used 
successfully in a 46-year-old woman with a 30-year history of sleep terrors and 
somnambulism. REM suppressant properties of the antidepressants would appear 
to be a rational approach to the control of nightmares, though the evidence is not 
convincing [98]. Given these therapeutic uncertainties with use of the antidepres-
sants for parasomnias and sleep related movement disorders, these drug classes are 
not first line treatments for these disorders and will not be discussed in depth here.
8.  The alpha 2 delta subunit neuronal voltage-gated calcium 
channel blockers
The two drugs in this class are gabapentin and pregabalin and will be dis-
cussed separately. These drugs are not used for management of parasomnias, but 
have gained increasing favor for use in restless legs syndrome and periodic limb 
movement disorder. The current recommendations of the Scientific and Medical 
Advisory Board of the Restless Legs Syndrome Foundation were recently published 
in Mayo Clinic Proceedings. The alpha 2 delta subunit neuronal voltage-gated 
calcium channel blockers were recommended as first line therapy for chronic 
persistent restless legs syndrome (RLS) [99].
8.1 Gabapentin
Gabapentin was approved in December 1993 by the Food and Drug 
Administration (FDA) for the adjunctive therapy of partial seizures. After initial 
approval gabapentin sales increased significantly due to off-label uses for treat-
ment of chronic pain syndromes [100]. In 2000 gabapentin was the top-selling 
anticonvulsant and ranked 17th in total expenditures among all drugs. In 2002 the 
FDA added the indication of postherpetic neuralgia, but by 2004 gabapentin sales 
had increased to 3 billion dollars per year [101]. In 2004 the US Department of 
Justice issued its largest fine to date ($430 million) to the Warner-Lambert group of 
pharmaceutical companies, manufacturer of gabapentin, for promoting gabapentin 
for uses not approved by the FDA [102]. In 2012 gabapentin enacarbil (a pro-drug 
with better absorption characteristics) received FDA approval for the treatment of 
restless legs syndrome and postherpetic neuralgia. By 2015 the use of gabapentin 
formulations had tripled from 2002 [103]. In 2017 gabapentin was the fifth most 
commonly prescribed medication in the United States [104].
Gabapentin has many desirable pharmacokinetic properties [105]. Mean 
maximum plasma concentrations were attained 2–3 hours after a 300–400 mg 
oral dose with a bioavailability of 60%, however, absorption kinetics are slowed 
and bioavailability decreased as the dose is increased. Gabapentin readily crosses 
the blood brain barrier due to its lipid solubility. It is not bound to plasma pro-
teins. The elimination half-life is dependent on renal clearance alone in a linear 
fashion. The drug does not affect the metabolism of other drugs or induce hepatic 
enzymes. The elimination half-life of gabapentin after a single oral dose of 
200–400 mg is about 5–7 hours with 80% of the dose recoverable unchanged in 
the urine. The most common adverse effects (significantly greater than placebo) 
are somnolence, dizziness, and ataxia. Happe et al. [106] reported efficacy of 
gabapentin given 2 hours before bedtime in restless legs syndrome in 2001. 
Subsequently, gabapentin enacarbil was found to be effective in a double-blind, 
placebo-controlled, multicenter study of 325 subjects [107]. This pro-drug (rap-
idly converted to gabapentin after absorption) sought to overcome the absorp-
tion deficiencies of gabapentin which was dependent upon active transport by a 
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low-capacity nutrient transport system expressed in a narrow region of the upper 
small intestine. Gabapentin enacarbil is actively transported by a high-capacity 
nutrient transporter located throughout the large and small intestine [108]. 
There was significant improvement in RLS symptoms with both the 600 mg and 
1200 mg doses of gabapentin enacarbil in the 12-week study compared to placebo. 
The most commonly reported adverse effects were dizziness and somnolence. 
Gabapentin enacarbil remains a preferable drug to generic gabapentin, however, 
cost concerns have made generic gabapentin more widely prescribed.
8.2 Pregabalin
Pregabalin and gabapentin share the same mechanism of action, inhibiting 
calcium influx into neuronal terminals and thus inhibiting the release of excitatory 
neurotransmitters. Orally dosed pregabalin is absorbed more rapidly than gabapen-
tin with maximal plasma concentrations achieved in 1 hour [108]. The absorption 
is linear with plasma concentrations increasing proportionally to dose and the 
bioavailability of 90% or greater. Neither drug binds to plasma proteins or inhibits 
hepatic enzymes, and both drugs are eliminated by renal excretion alone with 
elimination half-lives of less than 6 hours. At higher dose therapy (1800–4800 mg) 
gabapentin bioavailability can fall to 25–50% [109]. Pregabalin bioavailability 
remained above 90% across its entire dose range.
A randomized, double-blind, 6-week study of pregabalin in 137 patients with 
restless legs syndrome showed an effective daily dose for 50% of patients at 37.3 mg 
and for 90% of patients at 123.9 mg per day [110]. A higher proportion of respond-
ers to the Clinical Global Impressions-Improvement Scale (CGI-I) was seen at the 
two highest doses of pregabalin 300 and 450 mg per day. Dizziness and somnolence 
were the most common adverse effects, though dry mouth complaints also exceeded 
placebo. A second double-blind, placebo-controlled study [111] was performed 
almost simultaneously with the Allen et al. [110] study. This second study random-
ized 58 patients in a 12-week flexible-dose trial. The mean effective dose at the end 
of treatment was 322.5 mg per day. There was a significant improvement in the 
International Restless Legs Scale (IRLS) and Clinical Global Impression (CGI). 
Polysomnography measured a reduction in mean periodic limb movement index, 
improvement in sleep architecture, and decrease in wakefulness after sleep onset. 
Adverse effects were reported to be mild and included unsteadiness, somnolence, 
and headache.
From the earliest studies of pregabalin there has been a concern about cogni-
tive effects of this drug. Salinsky et al. [112] looked at this potential adverse effect 
in 32 healthy volunteers. The participants were randomized in a double-blind, 
parallel study receiving either pregabalin or placebo. Pregabalin was titrated over 
8 weeks to 600 mg per day. At baseline and after 12 weeks of treatment all subjects 
underwent cognitive testing. A battery of 14 tests were used including finger 
tapping, grooved pegboard, digit symbol, Stroop color-word, selective reminding, 
name learning, story recall, Wonderlic personnel, visual reaction time, controlled 
oral word association, divided attention, letter-number sequencing, profile of 
mood states and Portland neurotoxicity scale. Thirty subjects completed the trial. 
There was significant (p < 0.01) worsening in the treatment group on the objective 
Stroop-color-word test and controlled oral word association test, as well as, the 
subjective Portland neurotoxicity scale. While the study demonstrated cognitive 
effects, both the speed of the titration and the final dose were greater than this 
author’s current practice and the methodology of the treatment studies described 
here. This study, however, does demonstrate concerns over rapid dose increases and 
high dose therapy.
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9. The dopamine receptor agonists
The dopamine agonists have been the first line treatment of periodic limb 
movement disorder and restless legs syndrome for many years. It is only recently 
that the alpha 2 delta subunit neuronal voltage-gated calcium channel blockers have 
advanced to preferred therapy [99]. It has, however, been long appreciated that 
the dopamine receptor agonists have adverse effects [113]. Impulse control disor-
ders such as pathological gambling, hypersexuality, compulsive shopping, or an 
irresistible urge to wander have been identified in surveys [114]. The D3 dopamine 
receptor has been implicated in these behaviors [115], however, no dose response 
curve or dose related risk assessment has been established for these phenomena. A 
more pervasive and widespread adverse effect is the phenomena of augmentation. 
Augmentation manifests as earlier onset of RLS symptoms with decreased dura-
tion of benefit from medications and symptoms involving other parts of the body. 
Though the highest risk of augmentation occurs with short acting agents such as 
levodopa, current expert opinion is that augmentation will occur with all the cur-
rently available dopamine agonists over time [99].
9.1 Pramipexole
Pramipexole is a non-ergot dopamine agonist with higher affinity to D3 than D2 
or D4 receptor subtypes. It has FDA indications for Parkinson’s disease and restless 
leg syndrome [116]. It is rapidly absorbed and reaches peak plasma concentrations 
in 2 hours. If taken with a meal the absorption is delayed by about an hour. The bio-
availability of pramipexole is greater than 90%. Renal excretion is the primary route 
of elimination with 90% of the dose recovered unchanged in the urine. The half-life 
of pramipexole is 8 hours in young adults and 12 hours in the elderly. The most 
common adverse effect (in excess of placebo) was somnolence. The recommended 
final treatment dose after up-titration was 0.5 mg given 2–3 hours before bedtime. 
Though higher doses are used in practice, the risk of increasing augmentation with 
high dose therapy leads to concern about high dosing [68].
9.2 Rotigotine
Rotigotine is dispensed as a transdermal delivery system [117]. It is a non-ergo-
line dopamine agonist for the D3, D2, and D1 dopamine receptors approved by the 
FDA for use in RLS as well as Parkinson’s disease. When a patch is applied there is a 
3-hour delay before the drug is detected in plasma and the time to maximal plasm 
levels is 15–18 hours. Approximately 45% of the dose is released from the patch in 
24 hours. After removal of the patch the elimination half-life is 5–7 hours. Most roti-
gotine is eliminated in the urine as inactive conjugates. The highest recommended 
dose (for RLS) of rotigotine is 3 mg per 24 hours. The most common adverse effect 
was a skin reaction at the site of the patch, though nausea also exceeded placebo. 
The constant delivery system suppresses RLS augmentation temporarily though 
other medications may ultimately be needed for breakthrough symptoms [68].
9.3 Ropinirole
Ropinirole is a selective non-ergoline dopamine D3 much greater than D2 
receptor agonist [118]. It is rapidly absorbed but its bioavailability is only 50%. The 
maximal plasma concentrations are achieved in 0.5 to 4 hours (mean 1.5 hours). 
The drug is metabolized in the liver to inactive metabolites by the P450 iso-enzyme 
CYP1A2. The elimination half-life is 3 hours, though this can be variable and elderly 
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patients have 15% slower clearance. The drug is FDA approved for use in restless 
legs syndrome, as well as, Parkinson’s disease. The short half-life and duration of 
action of this drug can lead to tachyphylaxis and doses higher than recommended 
producing a high rate of augmentation in the author’s experience.
10. Prazosin
The American Academy of Sleep Medicine published a position paper on the treat-
ment of nightmare disorder in 2018 [119]. The position paper divided nightmares into 
those associated with post-traumatic stress disorder (PTSD) and those not associated 
with PTSD. Nightmares associated with PTSD are more difficult to suppress and thus 
a wide variety of behavioral and drug combinations have been used, beyond the capa-
bility of this chapter. The drugs that may be used in nightmare disorder in the absence 
of PTSD are benzodiazepines, not including clonazepam, and prazosin.
Prazosin is a quinazoline derivative and peripheral vasodilator [120]. Its vaso-
dilator properties are due to postsynaptic alpha adrenergic receptor blockade. 
Prazosin is extensively metabolized in the liver producing high first pass elimination 
and resultant low oral bioavailability after oral dosing. With an oral dose of 1 mg in 
normal subjects the bioavailability of prazosin ranged from 43.5 to 69.3% [121]. The 
mean elimination half-life is about 2.5 hours. Prazosin shows initial dose postural 
hypotension which disappears with continued administration.
On acute administration of prazosin, only very low levels crossed the blood–
brain barrier [122]. On chronic administration of high dose prazosin, however, 
prazosin apparently crossed the blood–brain barrier in adequate concentrations to 
affect the central alpha adrenergic receptor density in the cerebral cortex [123]. This 
effect would not have occurred without significant penetration of prazosin into 
the brain. There were a number of studies showing efficacy of prazosin in veterans 
with PTSD induced nightmares [119]. In contrast, however, there was a recent 
large randomized, placebo-controlled study with negative results [124], leading to 
uncertainty about this treatment.
11. The opioids
Various opioids have been used for intractable restless legs syndrome. These 
include propoxyphene [125]. tramadol [126], oxycodone [127], hydrocodone [128], 
and methadone [129]. Most of these have been used as adjunctive therapy, but 
methadone has been used in monotherapy. The mechanism of action of the opioids 
in RLS is unclear, however, it appears to work through a central dopaminergic neu-
rotransmission as dopamine receptor antagonists will block the therapeutic effect. 
The current opioid crisis has lent a stigma to chronic use of methadone that has dis-
couraged its use by many patients suffering with intractable restless legs syndrome. 
This is unfortunate as opioid therapy with management directed towards restless 
legs syndrome rather than chronic pain syndromes can be quite helpful [130]. The 
concern with long-term opioid therapy is the occult development or exacerbation 
of a sleep related breathing disorder. For this reason, all patients on chronic opioids 
should be clinically monitored for evidence of sleep apnea [131].
11.1 Methadone
Methadone is a synthetic opioid that is nearly equipotent with morphine, but 
with dramatically different pharmacokinetic characteristics [132]. Methadone 
Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy
16
is a racemic mixture of R and S-methadone with the R isomer being 8–50 times 
more potent. Methadone may prevent or attenuate opioid tolerance via its weak 
antagonist properties on the N-methyl-D-aspartate (NMDA) receptor. Methadone 
is rapidly absorbed with maximal plasma concentrations 2.5 to 4 hours after oral 
administration. The bioavailability of methadone is 70–80%, though this can 
vary depending on the degree of first pass metabolism. Methadone is hepatically 
metabolized to inactive metabolites by the cytochrome P450 enzymes, CYP3A4 and 
CYP2B6. The elimination half-life of methadone ranges from 5 to 130 hours with 
a mean of 20–35 hours. The elimination half-life of the R isomer is approximately 
25% longer than the S isomer. Methadone shows apparent autoinduction of its own 
metabolism. The half-life during chronic therapy is only 40% of the half-life with 
acute administration. A number of medications can either decrease or increase 
methadone levels via induction or inhibition of CYP3A4. Quantitative plasma levels 
may be necessary. Of note, there have been unintentional deaths with methadone. 
Many of these deaths occurred on the fifth day of regular dosing [133]. Prescribers 
need to be aware of methadone’s peculiar pharmacokinetics.
In practice doses of methadone from 5–40 mg daily have been used. Given 
the pharmacokinetics starting therapy at a small dose of 2.5–5 mg is appropriate 
with up-titration of the dose as needed for symptoms. Methadone in patients with 
intractable RLS can produce remarkable improvement [68, 129].
11.2 Oxycodone-naloxone
Constipation and bowel dysfunction is the prime adverse effect of long-term opi-
ate therapy. The combination of an opioid with a competitive mu receptor antagonist 
in a sustained release formulation is a unique answer to opioid adverse effects. The 
combination is also a tool against abuse of oxycodone since dissolution and injection 
results in naloxone having a much greater effect blocking mu receptors. A double-
blind, randomized, placebo-controlled trial with this formulation was performed 
with 276 RLS patients [134]. The study started participants on a dose of oxycodone 
5.0 mg and naloxone 2.5 mg twice a day increasing per each study site’s investigator 
to a maximal dose of oxycodone 40 mg and naloxone 20 mg. Adverse effects more 
than twice as frequent as placebo included fatigue, constipation, somnolence, dry 
mouth and pruritis. There was clear efficacy of the combination over placebo.
12. Conclusions
This chapter did not attempt to be all inclusive, as a full description of the phar-
macological interventions into sleep related movement disorders and parasomnias 
would fill the entire book. The chapter does attempt to provide pharmacological 
basis for treatment of the most challenging areas for pharmaceutical intervention, 
notably the REM sleep parasomnias and restless legs syndrome.
A challenge of REM sleep parasomnia management is the continuing use of clon-
azepam as first line therapy. This potent drug is effective, but due to its extremely 
long half-life, is prone to adverse effects in many patients. Unfortunately, the even 
more potent drug, triazolam, is too short acting and the two drugs (alprazolam and 
lorazepam) with duration of actions that are reasonable for the goal of suppress-
ing dream enactment are less potent than either triazolam or clonazepam, thus 
appearing to need higher doses. Unexpectedly, the observational experience of the 
University of Texas Southwestern Medical Center at Dallas Clinical Center for Sleep 
and Breathing Disorders has been that the efficacy of alprazolam is half the expected 
dose that was used in trials in Minneapolis. Retrospective review is in progress.
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The other pharmacological challenge is the management of severe persistent and 
intractable restless leg syndrome. In recent decades the algorithms for management 
have become clearer pointing to the early use of gabapentin and pregabalin and 
the use of opioids in intractable patients, however, there is a lag of that knowl-
edge reaching the medical community that is faced with these patients and their 
demands for treatment. This is another area where the growth of medical knowl-
edge is exceeding our educational capabilities.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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